#Sustainability #South Korea #Samsung Biologics #ESG Day #Incheon

Samsung Biologics Hosts Supplier ESG Day to Propel Decarbonization Efforts

On December 3, 2024, Samsung Biologics conducted its second Supplier ESG Day, aimed at fostering sustainable practices among its suppliers in the quest for decarbonization. This initiative reflects the commitment of the leading contract development and manufacturing organization (CDMO) to create a more sustainable healthcare industry, which is notorious for being one of the largest carbon emitters globally.

The virtual event attracted participation from over 82 suppliers, including major companies like Merck, Cytiva, Thermo Fisher, and Sartorius. This approach allowed Samsung Biologics to reach both domestic and international suppliers, reinforcing its commitment to comprehensive sustainability across its value chain.

CEO John Rim emphasized the responsibility of healthcare companies to lead sustainability efforts, stating, "As the healthcare industry is one of the largest carbon emitters, it is our responsibility to be at the forefront of efforts to promote sustainable value chains." This sentiment sets the tone for Samsung Biologics’ ongoing initiatives to bolster the ESG management of its suppliers, while also aiming for net-zero emissions by 2050.

During the event, Samsung Biologics shared its experiences and best practices in ESG management, highlighting its use of low-carbon technologies such as ultra-low NOx boilers and energy monitoring systems. Furthermore, the company is accelerating its transition towards renewable energy, evidenced by the installation of onsite solar panels at its facilities. These endeavors have not gone unnoticed; Samsung Biologics has received accolades such as the Terra Carta Seal from the Sustainable Markets Initiative (SMI) and holds an EcoVadis platinum rating, the highest rank available in sustainability performance.

The company has also taken significant steps in engaging its suppliers to contribute actively to building more sustainable and resilient global value chains. For this, it has encouraged its partners to stay ahead of various international standards, including the European Union’s Corporate Sustainability Due Diligence Directive and the International Financial Reporting Standards.

To bolster understanding of sustainability, Samsung Biologics invited external ESG specialists to share insights on ESG-related requirements. These experts focused on sustainability reporting and tools specifically designed for small and mid-sized companies, ensuring that all stakeholders can effectively contribute to the sustainability efforts.

In the coming months, Samsung Biologics looks forward to expanding these discussions and collaborations through initiatives that not only address immediate ESG concerns but also recognize the importance of building sustainable practices that will benefit future generations.

About Samsung Biologics:
Samsung Biologics, listed on the Korean Stock Exchange (KRX: 207940.KS), is known for its fully integrated CDMO services. From cell line development to final aseptic filling, the company provides seamless solutions tailored to biopharmaceutical partners. With CGMP-compliant facilities and an overall capacity of 604 kL following the completion of Bio Campus I, and an additional 180 kL set to open in Bio Campus II by April 2025, Samsung Biologics continues to invest in its infrastructure and capabilities. With a strong commitment to operational excellence and innovation, the company is poised to accommodate the ever-growing demands of biomanufacturing and provide unparalleled services to its clients worldwide.